Prothena Corporation plc
PRTA
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb cliniā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$9.58
Price+0.28%
$0.03
1Y
Price
Market Cap
$515.514m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-1488.2%
EBITDA Margin-1513.1%
Net Profit Margin-1680.1%
Free Cash Flow Margin-1488.2%
EBITDA Margin-1513.1%
Net Profit Margin-1680.1%
Free Cash Flow MarginRevenue
$11.786m
-91.3%
1y CAGR+8.7%
3y CAGR-11.7%
5y CAGREarnings
-$280.459m
-129.3%
1y CAGR-46.1%
3y CAGR-103.2%
5y CAGREPS
-$5.22
-130.0%
1y CAGR-41.3%
3y CAGR-100.7%
5y CAGRBook Value
$294.989m
$352.628m
Assets$57.639m
Liabilities$9.082m
DebtDebt to Assets
2.6%
-
Debt to EBITDAFree Cash Flow
-$188.221m
-25.2%
1y CAGR-20.1%
3y CAGR-69.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company